Ardelyx Corp (ARDX): Net earnings per share (EPS TTM)

ARDX (Ardelyx, Inc.) - company brandmark

Ardelyx, Inc. (ARDX) ensures the seamless delivery of nephrology medications to patients with complex pathologies. Growth in the customer base relies on Medicare decisions and the uniqueness of kidney and gastrointestinal therapies. The management's high level of competence in disputes with the FDA confirms the resilience of the strategy. On GURU.Markets, the company's TTM net income per share is available for analysis, where the -0.23 level captures the current state of profitability.

ARDX Ardelyx Corp Earnings per share for the last 12 months (07/04/2022 - 11/15/2026)

Analytical breakdowns and data insights for company Ardelyx Pharma (ARDX)

- stock price and consensus target price:
Stock Price Ardelyx Inc|ARDX - Analyst Median Target
- stock exchange capitalization data:
Market Capitalization Ardelyx|ARDX - Business Value
- business book valuation details:
Net Assets per Single Share Ardelyx|ARDX - Accounting Capitalization|Market Capitalization to Book Value Ratio ardelyx.com|ARDX - Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Ardelyx, Inc.|ARDX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Ardelyx Corp|ARDX - Company Aggregate Debts|Debt to Book Capitalization Ratio Ardelyx Corp|ARDX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Ardelyx|Quick Ratio ardelyx.com
- earnings and multiples data:
ARDX - Company Net Income|Expected Profit Ardelyx, Inc.|ARDX - Price to Earnings Ratio|Projected Price to Earnings ardelyx.com|ARDX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Ardelyx|ARDX - Operating profit before amortization|Net earnings per share for the last 12 months Ardelyx|ARDX - Earnings per share for the trailing year|Quarterly EPS earnings growth ardelyx.com|ARDX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Ardelyx, Inc.
- sales volume and revenue information:
ARDX - Company Sales Volume|Projected Sales Volume Ardelyx Inc|ARDX - Market Cap to Revenue|Forward Price-to-Revenue Multiple Ardelyx
Analysis of all company metrics:ARDX - Ardelyx
Flagship merchandise of Ardelyx Inc

Revenue growth from kidney disease treatments has pushed the Ardelyx, Inc. (ARDX) operating model into a zone of stability, despite its dependence on government insurance schemes. TTM net income per share measures the overall efficiency of the business by allocating total income to a single security, allowing investors to assess real value generation through TTM earnings per share dynamics.

Competing companies

Travere Therapeutics Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters ProKidney PROK|AKBA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months TVRD|Earnings per share for the last twelve months DiaMedica Therapeutics Inc.|Earnings per share for the last 12 months UNCY (Unicycive Therapeutics)|Net earnings per share (EPS TTM) RMTI|CVKD - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CDT (Conduit Therapeutics)|Calliditas (CALT) - Net earnings per one share for the last twelve months|RNLX - Earnings per share for the last twelve months|Earnings per one share for the last 12 months ZVSA